BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Report: Thailand strikes deal with Iran for safe passage of Hormuz- The Most Vital Crossroads in Olympic History
- How a Middle East War Becomes a Retail Price Hike
- How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- The Most Compelling Books of the 10 years
- Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- A definitive Bike Standoff: Decision in favor of Your Number one Ride
- Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
